Abstract: This invention relates to a method of treating a disease state selected from: Alzheimer's disease, Down's syndrome, mental retardation, memory defects, memory loss, pancreatic cancer, bone resorption disease, osteoporosis, sickle cell anemia, chronic kidney disease, diabetes, depression, and subsets of depression including: alcoholism, anxiety, obsessive compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia and substance abuse, in a mammal in need thereof, including a human, which comprises administering to such mammal a therapeutically effective amount of a selected substituted thiazol compound. The invention also relates to a method of enhancing cognition in a mammal in need thereof which comprises administering to such mammal a therapeutically effective amount of a selected substituted thiazol compound.

Abstract: Invented is a method of treating cancer and pre-cancerous syndromes in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

Abstract: Invented is a method for the preservation of human platelet lifespan and/or efficacy during storage which comprises the addition of an effective amount of a non-peptide TPO receptor agonists to a storage solution containing human platelets.

Abstract: The invention provides a fuel cell metallic separator, wherein the metallic plate's edges include a resin portion comprising the communication ports. The resin portion around the communication ports is shaped so as to be capable of interlocking with a fuel cell stack component adjacently located in a fuel cell system. The invention also provides a resin portion capable of press fitting or thermal bonding with adjacent a fuel cell stack components.

Abstract: SAF-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SAF-2 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: SAF-3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SAF-3 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: Design Improvements are disclosed which enhance the migrating combustion chamber engine's ability to achieve improved performance, obtain higher durability and cost less to manufacture. These include strip seals between the combustion chamber member and orbiting piston which are adapted to respond to the pressure of combustion to increase contact pressure and improve retention of the gases in the combustion chambers as well as improved porting located in at least one power block sidewall and cooperating with the migrating combustion chamber to convey hot combustion gasses from a combustion chamber to a corresponding secondary expansion chamber. The combustion chamber member may be formed of two reciprocable piston portions and a pair of separate alloy steel connecting bars coupling the piston portions together. The connecting bars made of a low thermal conductivity material to remain hot and aid in fuel evaporation. A one piece counterweight hub provides all required counterweights.